RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients

Genes and Cancer

Volumn 4, Issue 7-8, 2013, Pages 273-284

  Muniz, Viviane P ^a   Askeland, Ryan W ^b   Zhang, Xuefeng ^b   Reed, Sara M ^b   Tompkins, Van S ^b   Hagen, Jussara ^b   McDowell, Bradley D ^c   Button, Anna ^b   Smith, Brian J ^b   Weydert, Jamie A ^b   Mezhir, James J ^b   Quelle, Dawn E ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

ARF; chemoresistance; oxaliplatin; pancreatic ductal adenocarcinoma; RABL6A

Indexed keywords

BIOLOGICAL MARKER; OXALIPLATIN; RAB PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; RABL6A GENE;

EID: 84887421647     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913501074     Document Type: Article

References (45)

1. Hidalgo M.Pancreatic cancer.N Engl J Med. 2010;362:1605-17.
2. Jemal A,Siegel R,Xu J,Ward E.Cancer statistics, 2010.CA Cancer J Clin. 2010;60:277-300.
3. Oettle H,Post S,Neuhaus P,et al.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.JAMA. 2007;297:267-77.
4. Yeo CJ.Pancreatic cancer-in brief.Curr Probl Cancer. 2002;26:170.
5. Burris HA.Recent updates on the role of chemotherapy in pancreatic cancer.Semin Oncol. 2005;32 (4): S1-S3.
6. Conroy T,Desseigne F,Ychou M,et al.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med. 2011;364:1817-25.
7. Tompkins V,Hagen J,Zediak VP,Quelle DE.Identification of novel ARF binding proteins by two-hybrid screening.Cell Cycle. 2006;5:641-6.
8. Quelle DE,Zindy F,Ashmun RA,Sherr CJ.Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest.Cell. 1995;83:993-1000.
9. Sherr CJ.Divorcing ARF and p53: an unsettled case.Nat Rev Cancer. 2006;6:663-73.
10. Montalbano J,Jin WX,Sheikh MS,Huang Y.RBEL1 is a novel gene that encodes a nucleocytoplasmic ras superfamily GTP-binding protein and is overexpressed in breast cancer.J Biol Chem. 2007;282:37640-9.
11. Montalbano J,Lui K,Sheikh MS,Huang Y.Identification and characterization of RBEL1 subfamily of GTPases in the Ras superfamily involved in cell growth regulation.J Biol Chem. 2009;284:18129-42.
12. Bardeesy N,DePinho RA.Pancreatic cancer biology and genetics.Nat Rev Cancer. 2002;2:897-909.
13. Iacobuzio-Donahue CA,Maitra A,Olsen M,et al.Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.Am J Pathol. 2003;162:1151-1162.
14. Ishikawa M,Yoshida K,Yamashita Y,et al.Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells.Cancer Sci. 2005;96:387-93.
15. Garnett MJ,Edelman EJ,Heidorn SJ,et al.Systematic identification of genomic markers of drug sensitivity in cancer cells.Nature. 2012;483:570-87.
16. Barretina J,Caponigro G,Stransky N,et al.The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.Nature. 2012;483:603-7.
17. Chiu SJ,Lee YJ,Hsu TS,Chen WS.Oxaliplatin-induced gamma-H2AX activation via both p53-dependent and -independent pathways but is not associated with cell cycle arrest in human colorectal cancer cells.Chem Biol Interact. 2009;182:173-82.
18. William-Faltaos S,Rouillard D,Lechat P,Bastian G.Cell cycle arrest and apoptosis induced by oxaliplatin (L-OHP) on four human cancer cell lines.Anticancer Res. 2006;26:2093-9.
19. Zhang J,Yang PL,Gray NS.Targeting cancer with small molecule kinase inhibitors.Nat Rev Cancer. 2009;9:28-39.
20. Hanahan D,Weinberg RA.Hallmarks of cancer: the next generation.Cell. 2011;144:646-74.
21. Showalter SL,Charles S,Belin J,et al.Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future.Expert Opin Drug Deliv. 2010;7:273-84.
22. Costantino CL,Witkiewicz AK,Kuwano Y,et al.The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.Cancer Res. 2009;69:4567-72.
23. Richards NG,Rittenhouse DW,Freydin B,et al.HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.Ann Surg. 2010;252:499-506.
24. Sebastiani V,Ricci F,Rubio-Viquiera B,et al.Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.Clin Cancer Res. 2006;12:2492-7.
25. Kelber JA,Reno T,Kaushal S,et al.KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.Cancer Res. 2012;72:2554-64.
26. Perez-Mancera PA,Rust AG,van der Weyden L,et al.The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.Nature. 2012;486:266-70.
27. Hristov AC,Cope L,Di Cello F,et al.HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma.Mod Pathol. 2010;23:98-104.
28. Jamieson NB,Carter CR,McKay CJ,Oien KA.Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Clin Cancer Res. 2011;17:3316-31.
29. Seetharam RN,Sood A,Basu-Mallick A,Augenlicht LH,Mariadason JM,Goel S.Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.Anticancer Res. 2010;30:2531-8.
30. Takahashi M,Koi M,Balaguer F,Boland CR,Goel A.MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor.J Biol Chem. 2011;286:12157-65.
31. Wilson C,Purcell C,Seaton A,et al.Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-κB transcription and evasion of apoptosis.J Pharmacol Exp Ther. 2008;327:746-59.
32. Khan Z,Khan N,Varma AK,et al.Oxaliplatin-mediated inhibition of survivin increases sensitivity of head and neck squamous cell carcinoma cell lines to paclitaxel.Curr Cancer Drug Targets. 2010;10:660-9.
33. Assaf E,Verlinde-Carvalho M,Delbaldo C,et al.5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.Oncology. 2011;80:301-6.
34. Michalski CW,Erkan M,Sauliunaite D,et al.Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer.Br J Cancer. 2008;99:760-7.
35. Banerjee S,Azmi AS,Padhye S,et al.Structure-activity studies on therapeutic potential of thymoquinone analogs in pancreatic cancer.Pharm Res. 2010;27:1146-58.
36. Ying JE,Zhu LM,Liu BX.Developments in metastatic pancreatic cancer: is gemcitabine still the standard?.World J Gastroenterol. 2012;18:736-45.
37. Ko AH.FOLFIRINOX: a small step or a great leap forward?.J Clin Oncol. 2011;29:3727-9.
38. Chadha KS,Khoury T,Yu JH,et al.Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma.Ann Surg Oncol. 2006;13:933-9.
39. Vitale I,Galluzzi L,Castedo M,Kroemer G.Mitotic catastrophe: a mechanism for avoiding genomic instability.Nat Rev Mol Cell Biol. 2011;12:385-92.
40. Castedo M,Coquelle A,Vivet S,et al.Apoptosis regulation in tetraploid cancer cells.EMBO J. 2006;25:2584-95.
41. Bardeesy N,Aguirre AJ,Chu GC,et al.From the cover: both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.Proc Natl Acad Sci U S A. 2006;103:5947-52.
42. Korgaonkar C,Hagen J,Tompkins V,et al.Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.Mol Cell Biol. 2005;25:1258-71.
43. Pfaffl MW.A new mathematical model for relative quantification in real-time RT-PCR.Nucleic Acids Res. 2001;29 (9): e45.
44. Mercalli A,Sordi V,Formicola R,et al.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.Br J Cancer. 2007;96:1358-67.
45. Morgan MA,Meirovitz A,Davis MA,Kollar LE,Hassan MC,Lawrence TS.Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.Trans Oncol. 2008;1:36-43.